Uncategorized pages

Jump to navigation Jump to search

Showing below up to 50 results in range #4,351 to #4,400.

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)

  1. Scarbrough Bo rush for loss of 7 yards to the CLEMSON14 PENALTY CLEMSON offside (Bryant Austin) 4 yards to the CLEMSON3 NO PLAY 1ST DOWN ALABAMA. (1/1/18)
  2. Scheel C, et al. Cell (2011) cited as Ref 480 in DOI: 10.1038/s41392-020-0110-5
  3. Schlaberg R, et al, Arch. Pathol. Lab. Med. (2017), cited as Ref 9 in DOI: 10.3390/v12020211
  4. Schleiss MR, et al, Clin. Infect. Dis. (2019), cited as Ref 61 in DOI: 10.1016/j.jcv.2020.104372
  5. Schleiss MR (4th author of DOI: 10.1016/j.jcv.2020.104372)
  6. Schmidt M, et al. Ann. Oncol. (2010) cited as Ref 564 in DOI: 10.1038/s41392-020-0110-5
  7. Schneider E, et al, AWHONN Lifelines (2004), cited as Ref 28 in DOI: 10.1016/j.jcv.2020.104372
  8. Schon S, et al. Int. J. Cancer (2014) cited as Ref 400 in DOI: 10.1038/s41392-020-0110-5
  9. Schott AF, et al. Clin. Cancer Res. (2013) cited as Ref 579 in DOI: 10.1038/s41392-020-0110-5
  10. Schrader J, et al. Hepatology (2011) cited as Ref 515 in DOI: 10.1038/s41392-020-0110-5
  11. Schroeter EH, et al. Nature (1998) cited as Ref 179 in DOI: 10.1038/s41392-020-0110-5
  12. Schwartz DA, et al, Arch. Pathol. Lab. Med. (2020), cited as Ref 38 in DOI: 10.1016/j.jcv.2020.104372
  13. Schwartz DA, et al, Viruses (2020), cited as Ref 24 in DOI: 10.1016/j.jcv.2020.104372
  14. Scully S, et al. J. Neurosci. (2012) cited as Ref 421 in DOI: 10.1038/s41392-020-0110-5
  15. Sebastian M, et al. Cancer Immunol. Immunother. (2007) cited as Ref 561 in DOI: 10.1038/s41392-020-0110-5
  16. Section 1. Introduction (from DOI: 10.3390/v12020211)
  17. Section 1: Introduction (from DOI:10.14218/ERHM.2020.00023)
  18. Section 1: Introduction (from DOI: 10.1007/s11886-020-01292-3)
  19. Section 1: Introduction (from DOI: 10.1007/s11886-020-01293-2)
  20. Section 1: Introduction (from DOI: 10.1016/j.adro.2020.04.015)
  21. Section 1: Introduction (from DOI: 10.1016/j.clim.2020.108427)
  22. Section 1: Introduction (from DOI: 10.1016/j.jcv.2020.104372)
  23. Section 1: Introduction (from DOI: 10.1038/s41392-020-0110-5)
  24. Section 1: Introduction (from DOI: 10.1080/22221751.2020.1735265)
  25. Section 1: Introduction (from DOI: 10.1186/s13054-020-02882-x)
  26. Section 1: Introduction (from DOI: 10.3201/eid2605.200146)
  27. Section 2.1: Biological characteristics of CSCs (from DOI: 10.1038/s41392-020-0110-5)
  28. Section 2.1: Lessons from animal models (from DOI: 10.1016/j.jcv.2020.104372)
  29. Section 2.1: Selection of front-line personnel (from DOI: 10.1080/22221751.2020.1735265)
  30. Section 2.2: Congenital and perinatal infections with coronaviruses other than SARS-CoV-2 (from DOI: 10.1016/j.jcv.2020.104372)
  31. Section 2.2: Isolation and identification of CSCs (from DOI: 10.1038/s41392-020-0110-5)
  32. Section 2.2: Isolation and protection requirements (from DOI: 10.1080/22221751.2020.1735265)
  33. Section 2.3: Congenital and perinatal infections with SARS-CoV-2 (from DOI: 10.1016/j.jcv.2020.104372)
  34. Section 2.3: Isolation and observation of medical personnel after close contact with SARS-CoV-2 (from DOI: 10.1080/22221751.2020.1735265)
  35. Section 2. Traditional Methods of Diagnosing Infections (from DOI: 10.3390/v12020211)
  36. Section 2: Biology of SARS-CoV-2 (from DOI: 10.1007/s11886-020-01292-3)
  37. Section 2: COVID-19: Potential factors contributing to ICU delirium (from DOI: 10.1186/s13054-020-02882-x)
  38. Section 2: Epidemiological data of COVID-19 (from DOI: 10.1016/j.clim.2020.108427)
  39. Section 2: Is SARS-CoV-2 a congenital or perinatally-acquired pathogen for the neonate? (from DOI: 10.1016/j.jcv.2020.104372)
  40. Section 2: Methods (from DOI:10.14218/ERHM.2020.00023)
  41. Section 2: Methods (from DOI: 10.1016/j.adro.2020.04.015)
  42. Section 2: Protection requirements of medical personnel (from DOI: 10.1080/22221751.2020.1735265)
  43. Section 2: SARS-CoV-2 Biology and Clinical Implications (from DOI: 10.1007/s11886-020-01293-2)
  44. Section 2: The concept of CSCs (from DOI: 10.1038/s41392-020-0110-5)
  45. Section 3.1.1: Myocardial Injury and Heart Failure (from DOI: 10.1007/s11886-020-01293-2)
  46. Section 3.1.2: Arrhythmia (from DOI: 10.1007/s11886-020-01293-2)
  47. Section 3.1. Metagenomic Approach (from DOI: 10.3390/v12020211)
  48. Section 3.1: Cardiac Complications of COVID-19 (from DOI: 10.1007/s11886-020-01293-2)
  49. Section 3.1: Major transcription factors in CSCs (from DOI: 10.1038/s41392-020-0110-5)
  50. Section 3.1: Screening criteria (from DOI: 10.1080/22221751.2020.1735265)

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)

Retrieved from "http://wikibase.slis.ua.edu/wiki/Special:UncategorizedPages"